Antithyroid drug-induced immunomodulation in Graves' disease patients

Mirna Lechpammer, Josip Lukač, Stanislav Lechpammer, Zvonko Kusić

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The study was so designed as to determine the effect of low to medium daily doses of methimazole (10-20 mg per day) on the number and function of different types of immunocompetent cells in peripheral blood of patients with Graves' disease administered methimazole for the treatment of hyperthyroidism. The study included 127 patients with Graves' disease divided into three groups: group I of 29 thyrotoxic patients before the beginning of treatment; group II of 73 euthyroid patients under antithyroid treatment; and group III of 25 patients who remained euthyroid 8 weeks after therapy discontinuation. In group I, the proportion of CD4+ cells, proportion and number of granulocytes, and their ingestion and microbicidity as well as monocyte phagocytic activity and ingestion were decreased. The mentioned alterations were concluded to most likely be the consequence of the underlying autoimmune process. In group II, the proportion and number of CD8+ cells were increased, while the natural killer cell activity was impaired. Granulocyte microbicidity was suppressed as compared to group I, while the granulocyte phagocytic activity was impaired as compared to normal values. Compared to normal, monocyte microbicidity and phagocytic activity were also suppressed. Monocyte ingestion was suppressed as compared to groups I and III, regardless of the patients' thyroid hormone status. Study results strongly support the hypothesis of a direct immunosuppressive effect of methimazole in patients with Graves' disease rather than the theory favoring concomitant immunomodulation due to thyroid hormone decrease.

Original languageEnglish (US)
Pages (from-to)21-26
Number of pages6
JournalActa Medica Croatica
Volume56
Issue number1
StatePublished - 2002
Externally publishedYes

Fingerprint

Antithyroid Agents
Immunomodulation
Graves Disease
Methimazole
Granulocytes
Monocytes
Eating
Thyroid Hormones
Cell Count
Hyperthyroidism
Therapeutics
Immunosuppressive Agents
Natural Killer Cells
Reference Values

Keywords

  • Antithyroid agents-therapeutic use
  • Graves' disease-drug therapy
  • Graves' disease-immunology
  • Thyroid disease-drug therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lechpammer, M., Lukač, J., Lechpammer, S., & Kusić, Z. (2002). Antithyroid drug-induced immunomodulation in Graves' disease patients. Acta Medica Croatica, 56(1), 21-26.

Antithyroid drug-induced immunomodulation in Graves' disease patients. / Lechpammer, Mirna; Lukač, Josip; Lechpammer, Stanislav; Kusić, Zvonko.

In: Acta Medica Croatica, Vol. 56, No. 1, 2002, p. 21-26.

Research output: Contribution to journalArticle

Lechpammer, M, Lukač, J, Lechpammer, S & Kusić, Z 2002, 'Antithyroid drug-induced immunomodulation in Graves' disease patients', Acta Medica Croatica, vol. 56, no. 1, pp. 21-26.
Lechpammer, Mirna ; Lukač, Josip ; Lechpammer, Stanislav ; Kusić, Zvonko. / Antithyroid drug-induced immunomodulation in Graves' disease patients. In: Acta Medica Croatica. 2002 ; Vol. 56, No. 1. pp. 21-26.
@article{a93e11ec69724562b04fb0a363533235,
title = "Antithyroid drug-induced immunomodulation in Graves' disease patients",
abstract = "The study was so designed as to determine the effect of low to medium daily doses of methimazole (10-20 mg per day) on the number and function of different types of immunocompetent cells in peripheral blood of patients with Graves' disease administered methimazole for the treatment of hyperthyroidism. The study included 127 patients with Graves' disease divided into three groups: group I of 29 thyrotoxic patients before the beginning of treatment; group II of 73 euthyroid patients under antithyroid treatment; and group III of 25 patients who remained euthyroid 8 weeks after therapy discontinuation. In group I, the proportion of CD4+ cells, proportion and number of granulocytes, and their ingestion and microbicidity as well as monocyte phagocytic activity and ingestion were decreased. The mentioned alterations were concluded to most likely be the consequence of the underlying autoimmune process. In group II, the proportion and number of CD8+ cells were increased, while the natural killer cell activity was impaired. Granulocyte microbicidity was suppressed as compared to group I, while the granulocyte phagocytic activity was impaired as compared to normal values. Compared to normal, monocyte microbicidity and phagocytic activity were also suppressed. Monocyte ingestion was suppressed as compared to groups I and III, regardless of the patients' thyroid hormone status. Study results strongly support the hypothesis of a direct immunosuppressive effect of methimazole in patients with Graves' disease rather than the theory favoring concomitant immunomodulation due to thyroid hormone decrease.",
keywords = "Antithyroid agents-therapeutic use, Graves' disease-drug therapy, Graves' disease-immunology, Thyroid disease-drug therapy",
author = "Mirna Lechpammer and Josip Lukač and Stanislav Lechpammer and Zvonko Kusić",
year = "2002",
language = "English (US)",
volume = "56",
pages = "21--26",
journal = "Acta Medica Iugoslavica",
issn = "1330-0164",
publisher = "Academy of Medical Sciences of Croatica",
number = "1",

}

TY - JOUR

T1 - Antithyroid drug-induced immunomodulation in Graves' disease patients

AU - Lechpammer, Mirna

AU - Lukač, Josip

AU - Lechpammer, Stanislav

AU - Kusić, Zvonko

PY - 2002

Y1 - 2002

N2 - The study was so designed as to determine the effect of low to medium daily doses of methimazole (10-20 mg per day) on the number and function of different types of immunocompetent cells in peripheral blood of patients with Graves' disease administered methimazole for the treatment of hyperthyroidism. The study included 127 patients with Graves' disease divided into three groups: group I of 29 thyrotoxic patients before the beginning of treatment; group II of 73 euthyroid patients under antithyroid treatment; and group III of 25 patients who remained euthyroid 8 weeks after therapy discontinuation. In group I, the proportion of CD4+ cells, proportion and number of granulocytes, and their ingestion and microbicidity as well as monocyte phagocytic activity and ingestion were decreased. The mentioned alterations were concluded to most likely be the consequence of the underlying autoimmune process. In group II, the proportion and number of CD8+ cells were increased, while the natural killer cell activity was impaired. Granulocyte microbicidity was suppressed as compared to group I, while the granulocyte phagocytic activity was impaired as compared to normal values. Compared to normal, monocyte microbicidity and phagocytic activity were also suppressed. Monocyte ingestion was suppressed as compared to groups I and III, regardless of the patients' thyroid hormone status. Study results strongly support the hypothesis of a direct immunosuppressive effect of methimazole in patients with Graves' disease rather than the theory favoring concomitant immunomodulation due to thyroid hormone decrease.

AB - The study was so designed as to determine the effect of low to medium daily doses of methimazole (10-20 mg per day) on the number and function of different types of immunocompetent cells in peripheral blood of patients with Graves' disease administered methimazole for the treatment of hyperthyroidism. The study included 127 patients with Graves' disease divided into three groups: group I of 29 thyrotoxic patients before the beginning of treatment; group II of 73 euthyroid patients under antithyroid treatment; and group III of 25 patients who remained euthyroid 8 weeks after therapy discontinuation. In group I, the proportion of CD4+ cells, proportion and number of granulocytes, and their ingestion and microbicidity as well as monocyte phagocytic activity and ingestion were decreased. The mentioned alterations were concluded to most likely be the consequence of the underlying autoimmune process. In group II, the proportion and number of CD8+ cells were increased, while the natural killer cell activity was impaired. Granulocyte microbicidity was suppressed as compared to group I, while the granulocyte phagocytic activity was impaired as compared to normal values. Compared to normal, monocyte microbicidity and phagocytic activity were also suppressed. Monocyte ingestion was suppressed as compared to groups I and III, regardless of the patients' thyroid hormone status. Study results strongly support the hypothesis of a direct immunosuppressive effect of methimazole in patients with Graves' disease rather than the theory favoring concomitant immunomodulation due to thyroid hormone decrease.

KW - Antithyroid agents-therapeutic use

KW - Graves' disease-drug therapy

KW - Graves' disease-immunology

KW - Thyroid disease-drug therapy

UR - http://www.scopus.com/inward/record.url?scp=0036404966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036404966&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 21

EP - 26

JO - Acta Medica Iugoslavica

JF - Acta Medica Iugoslavica

SN - 1330-0164

IS - 1

ER -